Rate Video

BTOG 2020 | Actionable lung cancer targets

Stephen Liu • 30 Jan 2020

Lung Cancer Non-Small Cell Lung Cancer Capmatinib Crizotinib Larotrectinib Tepotinib

Stephen Liu, MD, MedStar Georgetown University Hospital, Washington, DC, actionable targets for the treatment of non-small cell lung cancer (NSCLC), such as MET and RET. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

ALTA-1L: brigatinib vs crizotinib in ALK+ aNSCLC

Stephen Liu • 30 Jan 2020

A shifting paradigm: lung cancer

Stephen Liu • 30 Jan 2020

Stephen Liu: BTOG highlights

Stephen Liu • 30 Jan 2020

Managing ALK+ NSCLC

Stephen Liu • 30 Jan 2020

Related Videos

Updates on MRx0518 + pembro in patients with resistance to therapy

Alex Stevenson • 27 Nov 2020

STIMULI trial update at ESMO 2020

Dirk De Ruysscher • 16 Nov 2020

Exciting updates at the Gathering around Cancer meeting

Jarushka Naidoo • 4 Nov 2020

Osimertinib for EGFR-mutant lung cancer

Jarushka Naidoo • 4 Nov 2020